RT Journal Article
SR Electronic
T1 Unveiling Endoglin non canonical regulation: spotlight on the new role of the uPAR pathway
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.01.28.24301864
DO 10.1101/2024.01.28.24301864
A1 Munsch, Gaëlle
A1 Proust, Carole
A1 Deiber, Clémence
A1 Meguerditchian, Caroline
A1 Caro, Ilana
A1 Tusseau, Maud
A1 Guilhem, Alexandre
A1 Mohamed, Shirine
A1 INVENT consortium
A1 Goyenvalle, Aurélie
A1 Debette, Stéphanie
A1 Jaspard-Vinassa, Béatrice
A1 Dupuis-Girod, Sophie
A1 Trégouët, David-Alexandre
A1 Soukarieh, Omar
YR 2024
UL http://medrxiv.org/content/early/2024/07/26/2024.01.28.24301864.abstract
AB Endoglin, encoded by ENG, is a transmembrane glycoprotein crucial for endothelial cell biology. Loss-of-function ENG variants cause Hereditary Hemorrhagic Telangiectasia (HHT). Despite advances in HHT diagnosis and management, the molecular origin of some cases and the source of clinical heterogeneity remain unclear.We propose a comprehensive in silico analysis of all 5’UTR ENG single nucleotide variants that could lead to Endoglin deficiency by altering upstream Open Reading Frames (upORFs). Experimentally, we confirm that variants creating uAUG-initiated overlapping upORFs associate with reduced Endoglin levels in vitro and characterize the effect of a uCUG-creating variant identified in two suspected HHT patients.Using plasma proteogenomics resources, we identify eight loci associated with soluble Endoglin levels, including ABO and uPAR-pathway loci and experimentally demonstrate the association between uPAR and Endoglin in endothelial cells.This study provides new insights into Endoglin’s molecular determinants, opening avenues for improved HHT management and other diseases involving Endoglin.Key pointsNew insights on the characterization of ENG non-coding variants, in particular those altering upstream Open Reading Frames in the 5’UTR.Leverage of large-scale plasma proteogenomics results combined with functional assays revealed new actors in Endoglin regulation.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis project was carried out in the framework of the French National Research Agency (ANR) ANR-23-CE17-0042-01 program as part of the ENDOMORF project and of the INSERM GOLD Cross-Cutting program (D-A.T.). O.S was financially supported by a grant of the Lefoulon-Delalande Foundation. IC was supported by the Digital Public Health Graduate Program (DPH), a PhD program supported by the French Investment for the Future Program (grant no. 17-EURE-0019). The 3C proteomics project was supported by a grant overseen by the French National Research Agency (ANR) as part of the (Investment for the Future Programme) ANR-18-RHUS-0002 and by the Precision and global vascular brain health institute funded by the France 2030 investment plan as part of the IHU3 initiative under grant agreement ANR-23-IAHU-0001. Statistical analyses benefited from the CBiB computing centre of the University of Bordeaux.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:These resources include 10,708 participants from the Fenland study, 35,559 Icelander participants of the Decode project, and 1,056 population-based participants of the 3C-Dijon study.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesENG constructs generated during this study are available upon request by email from the corresponding author (omar.soukarieh{at}inserm.fr).